Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites
- PMID: 15598764
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites
Abstract
Data from several countries indicate that 1% to 2% of Ashkenazi Jews carry a pathogenic ancestral mutation of the tumor suppressor gene BRCA1. However, the prevalence of BRCA1 mutations among non-Ashkenazi Whites is uncertain. We estimated mutation carrier prevalence in U.S. non-Hispanic Whites, specific for Ashkenazi status, using data from two population-based series of San Francisco Bay Area patients with invasive cancers of the breast or ovary, and data on breast and ovarian cancer risks in Ashkenazi and non-Ashkenazi carriers. Assuming that 90% of the BRCA1 mutations were detected, we estimate a carrier prevalence of 0.24% (95% confidence interval, 0.15-0.39%) in non-Ashkenazi Whites, and 1.2% (95% confidence interval, 0.5-2.6%) in Ashkenazim. When combined with U.S. White census counts, these prevalence estimates suggest that approximately 550,513 U.S. Whites (506,206 non-Ashkenazim and 44,307 Ashkenazim) carry germ line BRCA1 mutations. These estimates may be useful in guiding resource allocation for genetic testing and genetic counseling and in planning preventive interventions.
Similar articles
-
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.Hum Mol Genet. 1998 May;7(5):801-5. doi: 10.1093/hmg/7.5.801. Hum Mol Genet. 1998. PMID: 9536083
-
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.N Engl J Med. 1997 May 15;336(20):1401-8. doi: 10.1056/NEJM199705153362001. N Engl J Med. 1997. PMID: 9145676
-
The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data.Cancer. 2001 Jul 15;92(2):440-5. doi: 10.1002/1097-0142(20010715)92:2<440::aid-cncr1340>3.0.co;2-o. Cancer. 2001. PMID: 11466700
-
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.JAMA. 2007 Dec 26;298(24):2869-76. doi: 10.1001/jama.298.24.2869. JAMA. 2007. PMID: 18159056
-
Hereditary ovarian cancer in Ashkenazi Jews.Fam Cancer. 2004;3(3-4):259-64. doi: 10.1007/s10689-004-9552-0. Fam Cancer. 2004. PMID: 15516850 Review.
Cited by
-
Genetic architecture of complex traits and disease risk predictors.Sci Rep. 2020 Jul 21;10(1):12055. doi: 10.1038/s41598-020-68881-8. Sci Rep. 2020. PMID: 32694572 Free PMC article.
-
BRCA2 variants and cardiovascular disease in a multi-ethnic study.BMC Med Genet. 2012 Jul 18;13:56. doi: 10.1186/1471-2350-13-56. BMC Med Genet. 2012. PMID: 22809218 Free PMC article.
-
Prevalence of the most frequent BRCA1 mutations in Polish population.J Appl Genet. 2011 Aug;52(3):325-30. doi: 10.1007/s13353-011-0040-6. Epub 2011 Apr 19. J Appl Genet. 2011. PMID: 21503673 Free PMC article.
-
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.J Clin Oncol. 2014 Mar 10;32(8):783-90. doi: 10.1200/JCO.2013.49.3726. Epub 2014 Feb 10. J Clin Oncol. 2014. PMID: 24516018 Free PMC article. Clinical Trial.
-
Personalized Systemic Therapies in Hereditary Cancer Syndromes.Genes (Basel). 2023 Mar 9;14(3):684. doi: 10.3390/genes14030684. Genes (Basel). 2023. PMID: 36980956 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Molecular Biology Databases
Miscellaneous